MedTrace Logo

Ultrasound-guided Infraclavicular Block With Lidocaine or Ropivacaine for Closed Reduction of Distal Radius Fractures

NCT06379490 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2025-06-26

No results posted yet for this study

Summary

To investigate the feasibility of the lateral infraclavicular plexus brachialis (LIC) block for acute closed reduction of distal radius fractures, the investigators will compare the pain-relieving and muscle-relaxing properties of the LIC block with short- and long-acting local anesthetics in different concentrations but at the same volume. In addition to motor and sensory blockade during repositioning, feasibility will also be assessed by other patient-related and block-related factors, as well as by factors related to the repositioning and plastering procedure.

Conditions

  • Distal Radius Fractures
  • Lidocaine
  • Ropivacaine
  • Fracture Dislocation
  • Closed Reduction of Fracture and Application of Plaster Cast
  • Colles' Fracture

Interventions

DRUG

Ropivacaine 0.2% Injectable Solution

30 ml of Ropivacaine 0.2% = 60 mg ropivacaine

DRUG

Lidocaine epinephrine

30 ml of Lidocaine 1% with 5 μg/ml epinephrine = 300 mg lidocaine + 150 μg epinephrine

DRUG

Ropivacaine 0.5% Injectable Solution

30 mL of Ropivacaine 0.5% = 150 mg Ropivacaine

Sponsors & Collaborators

  • Nordsjaellands Hospital

    lead OTHER

Principal Investigators

  • Anders K. Nørskov, PhD · Copenhagen University Hospital - North Zealand

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-23
Primary Completion
2025-06-18
Completion
2025-06-18

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06379490 on ClinicalTrials.gov